Loxo Oncology Inc. (NASDAQ:LOXO) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Saturday. According to Zacks, “Loxo Oncology, Inc. is a biopharmaceutical company. It develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Loxo Oncology, Inc. is […]
